Hansoh Pharma reports ESGO 2026 PSOC data for B7-H4 ADC mocertatug rezetecan HS-20089

Reuters08:03

Hansoh Pharma reports ESGO 2026 PSOC data for B7-H4 ADC mocertatug rezetecan HS-20089

Hansoh Pharmaceutical Group Co., Ltd. reported data from two open-label studies of mocertatug rezetecan (HS-20089/GSK5733584), a B7-H4-targeted antibody-drug conjugate, in heavily pretreated patients with platinum-sensitive ovarian cancer. The results were presented at ESGO 2026: a Phase 2 monotherapy poster (HS-20089-201) and a Phase 1 combination study with bevacizumab (HS-20089-103) selected for a late-breaking abstract mini-oral session. In the Phase 2 PSOC cohort, confirmed overall response rate was 64.5% at a median follow-up of 16.6 months, with median duration of response 13.8 months and median progression-free survival 14.1 months; the most common grade 3 or higher treatment-emergent adverse events were hematologic laboratory abnormalities. In the Phase 1 PSOC cohort receiving the combination, confirmed overall response rate was 72.2% at a median follow-up of 3.9 months, and no new or overlapping toxicity was reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on February 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614895895?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-28 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614895895","market":"nz","top_or_hot":-1,"title":"Hansoh Pharma reports ESGO 2026 PSOC data for B7-H4 ADC mocertatug rezetecan HS-20089","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma reports ESGO 2026 PSOC data for B7-H4 ADC mocertatug rezetecan HS-20089\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. reported data from two open-label studies of mocertatug rezetecan (HS-20089/GSK5733584), a B7-H4-targeted antibody-drug conjugate, in heavily pretreated patients with platinum-sensitive ovarian cancer. The results were presented at ESGO 2026: a Phase 2 monotherapy poster (HS-20089-201) and a Phase 1 combination study with bevacizumab (HS-20089-103) selected for a late-breaking abstract mini-oral session. In the Phase 2 PSOC cohort, confirmed overall response rate was 64.5% at a median follow-up of 16.6 months, with median duration of response 13.8 months and median progression-free survival 14.1 months; the most common grade 3 or higher treatment-emergent adverse events were hematologic laboratory abnormalities. In the Phase 1 PSOC cohort receiving the combination, confirmed overall response rate was 72.2% at a median follow-up of 3.9 months, and no new or overlapping toxicity was reported.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on February 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma reports ESGO 2026 PSOC data for B7-H4 ADC mocertatug rezetecan HS-20089</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma reports ESGO 2026 PSOC data for B7-H4 ADC mocertatug rezetecan HS-20089\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-28 08:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma reports ESGO 2026 PSOC data for B7-H4 ADC mocertatug rezetecan HS-20089\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. reported data from two open-label studies of mocertatug rezetecan (HS-20089/GSK5733584), a B7-H4-targeted antibody-drug conjugate, in heavily pretreated patients with platinum-sensitive ovarian cancer. The results were presented at ESGO 2026: a Phase 2 monotherapy poster (HS-20089-201) and a Phase 1 combination study with bevacizumab (HS-20089-103) selected for a late-breaking abstract mini-oral session. In the Phase 2 PSOC cohort, confirmed overall response rate was 64.5% at a median follow-up of 16.6 months, with median duration of response 13.8 months and median progression-free survival 14.1 months; the most common grade 3 or higher treatment-emergent adverse events were hematologic laboratory abnormalities. In the Phase 1 PSOC cohort receiving the combination, confirmed overall response rate was 72.2% at a median follow-up of 3.9 months, and no new or overlapping toxicity was reported.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on February 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260228:nNDL4T2ShM:1","article_id":"2614895895","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614895895","pubTimestamp":1772237002,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharmaceutical Group Co., Ltd. reported data from two open-label studies of mocertatug rezetecan , a B7-H4-targeted antibody-drug conjugate, in heavily pretreated patients with platinum-sensitive ovarian cancer. The results were presented at ESGO 2026: a Phase 2 monotherapy poster  and a Phase 1 combination study with bevacizumab  selected for a late-breaking abstract mini-oral session. In the Phase 2 PSOC cohort, confirmed overall response rate was 64.5% at a median follow-up of 16.6 months, with median duration of response 13.8 months and median progression-free survival 14.1 months; the most common grade 3 or higher treatment-emergent adverse events were hematologic laboratory abnormalities. In the Phase 1 PSOC cohort receiving the combination, confirmed overall response rate was 72.2% at a median follow-up of 3.9 months, and no new or overlapping toxicity was reported.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Wh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","03692":"翰森制药","BK1589":"北水核心资产"},"translate_title":"豪森制药报告B7-H4 ADC mocertatug rezetecan HS-20089的ESGO 2026 PSOC数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharma reports ESGO 2026 PSOC data for B7-H4 ADC mocertatug rezetecan HS-20089\n    \n\n        Hansoh Pharmaceutical Group Co., Ltd. reported data from two open-label studies of mocertatug rezetecan (HS-20089/GSK5733584), a B7-H4-targeted antibody-drug conjugate, in heavily pretreated patients with platinum-sensitive ovarian cancer. The results were presented at ESGO 2026: a Phase 2 monotherapy poster (HS-20089-201) and a Phase 1 combination study with bevacizumab (HS-20089-103) selected for a late-breaking abstract mini-oral session. In the Phase 2 PSOC cohort, confirmed overall response rate was 64.5% at a median follow-up of 16.6 months, with median duration of response 13.8 months and median progression-free survival 14.1 months; the most common grade 3 or higher treatment-emergent adverse events were hematologic laboratory abnormalities. In the Phase 1 PSOC cohort receiving the combination, confirmed overall response rate was 72.2% at a median follow-up of 3.9 months, and no new or overlapping toxicity was reported.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on February 28, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614895895","isCrawlerRequest":true}